Pricing Log in Create free account

Sol-Gel Technologies Ltd. (SLGL) vs Vanda Pharmaceuticals Inc. (VNDA)

Sol-Gel Technologies Ltd. and Vanda Pharmaceuticals Inc. are both Biotechnology companies. Vanda Pharmaceuticals Inc. is the larger, with a market value of $231.0M against $199.8M — 1.2× the size. Vanda Pharmaceuticals Inc. grew revenue faster over the last twelve months: 8.11% against −92.5%. Vanda Pharmaceuticals Inc. has the higher net margin (−119.9% vs −910.1%) and the higher return on invested capital (−180.2% vs −6,630.2%). Across the 18 metrics below, Sol-Gel Technologies Ltd. leads on 9 and Vanda Pharmaceuticals Inc. on 9.

Valuation

Metric SLGL VNDA Biotechnology median
P/E n/m n/m 10.60
P/S 111.18 1.01 9.40
P/B 4.15 1.16 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 120.87 0.40 9.02
Earnings yield (9.24%) (121.02%) (32.88%)
Free cash flow yield (10.66%) (64.93%) (23.13%)

Profitability

Metric SLGL VNDA Biotechnology median
Gross margin 100.00% 93.59% 68.51%
Operating margin (986.96%) (77.59%) 0.00%
Net margin (910.14%) (119.87%) 0.00%
Free cash flow margin (1,185.18%) (65.41%) 0.00%
Return on equity (40.85%) (82.55%) (51.96%)
Return on assets (35.11%) (55.89%) (46.06%)
Return on invested capital (6,630.24%) (180.19%) 0.00%

Growth

Metric SLGL VNDA Biotechnology median
Revenue growth (TTM) (92.50%) 8.11% 6.76%
EPS growth (last fiscal year) 42.37% (1,033.33%) 29.88%
Revenue growth, 5-year CAGR 17.19% (2.73%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric SLGL VNDA Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 10.37 1.54 4.97
Net debt to EBITDA 3.23 1.84 1.01

Dividend

Metric SLGL VNDA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric SLGL VNDA Biotechnology median
Market cap 199.75m 230.99m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack